De Bie Caroline
Genzyme Corporate Affairs Europe, Ikaroslaan, Belgium.
Regen Med. 2007 Jan;2(1):95-7. doi: 10.2217/17460751.2.1.95.
Finding solutions for patients with unmet needs is at the heart of Genzyme's innovative medical research. While small molecules and enzyme-replacement therapies have made significant strides in improving patients' quality of life and expectancy, the solutions to many conditions, such as heart disease or CNS diseases, rely on the capacity of the body to regenerate cells. Cell and gene therapy lend themselves well to providing solutions for these illnesses with no current cure, by harnessing the body's natural ability to heal. Promising research in these fields continues to evolve and constitutes a long-term investment in addressing serious unmet medical needs in various therapeutic areas. Over the past 15 years, Genzyme has established itself as a pioneer in shaping the research and commercial application of cell and gene therapy. Genzyme's first commercially available innovative cell therapies--Carticel and Epicel--have provided a solid foundation to move into new, cutting-edge areas.
为满足未被满足需求的患者寻找解决方案是健赞创新医学研究的核心。虽然小分子药物和酶替代疗法在改善患者生活质量和预期寿命方面取得了重大进展,但许多病症(如心脏病或中枢神经系统疾病)的解决方案依赖于身体再生细胞的能力。细胞和基因疗法通过利用人体自身的愈合能力,非常适合为这些目前尚无治愈方法的疾病提供解决方案。这些领域中前景广阔的研究不断发展,是应对各个治疗领域严重未被满足的医疗需求的一项长期投资。在过去15年里,健赞已成为细胞和基因疗法研究及商业应用领域的先驱。健赞首批可商业化的创新细胞疗法——Carticel和Epicel——为进军新的前沿领域奠定了坚实基础。